

## SARS-CoV-2


# COVID-19 Delta Variant Pseudovirus Neutralizing Antibody Assay (Luciferase)

Catalog # DE0007      Size 1 Kit

## Applications


### Neutralization

SARS-CoV-2 delta variant spike pseudovirus expressing luciferase is treated with humanized monoclonal antibody 7F7, and then added into 293T-ACE cells.



### Neutralization

RBD-binding IgG responses in mouse sera collected 35 days and 42 days after immunization with 5 ug or 20 ug COVID-19 RBD SAM LNP no adjuvant (ppopV0) and 5 ug or 20 ug COVID-19 RBD SAM plus adjuvant (ppopV1).



## Specification

### Product Description

COVID-19 Delta Variant Pseudovirus Neutralizing Antibody Assay (Luciferase) provides a highly sensitive and quantitative measurement of neutralizing antibodies.

### Supplied Product

Kit content:

1 kit is sufficient for 100 assays in 24 well plates

1. 293T-hACE2 cell,  $2 \times 10^6$  cells/vial, FBS with 10% DMSO

2. SARS-CoV-2 Delta Variant Pseudovirus Expressing Luciferase

**Materials Required But NOT Supplied**

1. SARS-CoV-2 Monoclonal Antibody, Cat# MAB22854-M07, Abnova
2. ZymeFree™ Enzyme Free Cell Dissociation Reagent, Cat# TCL028-100ML, HIMEDIA
3. DMEM culture medium containing 10% FBS (complete medium)
4. Luciferase Assay System, Cat# E1500, Promega
  - a. Luciferase Assay Substrate (lyophilized)
  - b. Luciferase Assay Buffer
  - c. Luciferase Cell Culture Lysis Reagent, 5X
5. TC-Treated 24 Well Plates, Cat# 3524, Corning
6. OptiPlate™-96, Cat# 6005290, PerkinElmer

**Variant**

B.1.617.2

**Suitable Sample**

1. Immunized Serum
2. Infected Serum
3. Neutralizing Antibodies
4. Peptide Inhibitors or Proteins
5. Compounds Targeting Spike Induced Cell Fusion

**Sample Volume**

10-50 uL (please check sample source)

**Detection Method**

Luciferase Activity

**Technology**[Pseudovirus](#)**Regulatory Status**

For research use only (RUO)

**Storage Instruction**

293T-hACE2 cell Store at liquid nitrogen.  
Pseudovirus Store at -80°C.  
Aliquot to avoid repeated freezing and thawing.

## Applications

- Neutralization

SARS-CoV-2 delta variant spike pseudovirus expressing luciferase is treated with humanized monoclonal antibody 7F7, and then added into 293T-ACE cells.

- Neutralization

RBD-binding IgG responses in mouse sera collected 35 days and 42 days after immunization with 5 ug or 20 ug COVID-19 RBD SAM LNP no adjuvant (ppopV0) and 5 ug or 20 ug COVID-19 RBD SAM plus adjuvant (ppopV1).